• HOME

  • MEMBER'S PHOTO EXHIBIT

  • MEMBERSHIP

    • New Membership
  • CLUB CALENDAR

  • TBS SWAP-SELL

  • UPCOMING EVENTS

    • WORKSHOP SIGNUP
    • VOLUNTEER SIGNUP
  • CLUB STUFF

    • BONSAI CARE GUIDE
    • NEWSLETTERS
    • TBS LIBRARY
    • BONSAI LINKS
  • CONTACT

  • PHOTOS

  • TBS Forum

  • More

    Use tab to navigate through the menu items.
    • Facebook TBS
    To see this working, head to your live site.
    • All Posts
    • My Posts
    Mary kudro
    Jul 21, 2021

    First-in-Class Proteasome Inhibitor for Multiple Myeloma

    in Let's Talk Bonsai


    Bortezomib is an anticancer agent currently approved as the second line in the treatment of multiple myeloma and recently (December 2006 in the US) in the treatment of mantle cell lymphoma. The usually varies from branded to non-branded (generic) drugs.

    This proteasome inhibitor is usually given as a subcutaneous injection, but may also be given into the vein (intravenously). Bortezomib is most often administered with the steroid dexamethasone. It may also be administered in certain other combinations, such as with the chemotherapy drug cyclophosphamide, or the immunomodulatory drug thalidomide (VTD).

    0 comments
    0
    0 comments
    BACK TO TOP

    © 2019 by TBS